Example: Heart Attack

Clinical Trials on Epidermolysis Bullosa

Total 93 results

NCT04491604

Recruiting

The Objective of This Study is to Compare the Efficacy and Safety of Beremagene Geperpavec (B-VEC) Topical Gel With That of Placebo for the Treatment of Dystrophic Epidermolysis Bullosa (DEB).

Conditions: Dystrophic Epidermolysis Bullosa; Recessive Dystrophic Epidermolysis Bullosa; Dominant Dystrophic Epidermolysis Bullosa
NCT04285294

Not yet recruiting

Molecular Signatures of Cutaneous Squamous Cell Carcinoma During Recessive Dystrophic Epidermolysis Bullosa

Conditions: Recessive Dystrophic Epidermolysis Bullosa
NCT04227106

Recruiting

Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Conditions: Epidermolysis Bullosa; Recessive Dystrophic Epidermolysis Bullosa
NCT04217538

Completed

Observational Study of a Cohort of Patients With Hereditary Epidermolysis Bullosa

Conditions: Epidermolysis Bullosa
NCT04213261

Recruiting

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa

Conditions: Recessive Dystrophic Epidermolysis Bullosa
NCT04213703

Recruiting

A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa

Conditions: Epidermolysis Bullosa; Epidermolysis Bullosa Simplex; Epidermolysis Bullosa Dystrophica
NCT04214002

Recruiting

The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)

Conditions: Dystrophic Epidermolysis Bullosa; DEB - Dystrophic Epidermolysis Bullosa
NCT04186650

Enrolling by invitation

Ex Vivo Gene Therapy Clinical Trial for RDEB Using Genetically Corrected Autologous Skin Equivalent Grafts

Conditions: Epidermolysis Bullosa Dystrophica, Recessive
NCT04177498

Not yet recruiting

Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC

Conditions: Recessive Dystrophic Epidermolysis Bullosa
NCT04173650

Not yet recruiting

MSC EVs in Dystrophic Epidermolysis Bullosa

Conditions: Dystrophic Epidermolysis Bullosa
NCT04171661

Active, not recruiting

Self-Assembled Skin Substitute for the Treatment of Epidermolysis Bullosa

Conditions: Epidermolysis Bullosa Dystrophica
NCT04153630

Active, not recruiting

Safety Study and Preliminary Efficacy of Infusion Haploidentical Mesenchymal Stem Cells Derived From Bone Marrow for Treating Recessive Dystrophic Epidermolysis Bullosa

Conditions: Epidermolysis Bullosa Dystrophica, Recessive
NCT04140786

Recruiting

Optimizing IV Gentamicin in JEB

Conditions: Junctional Epidermolysis Bullosa
NCT03942250

Completed

Uses of Irradiated Human Amniotic Membrane in the Treatment of Dystrophic Epidermolysis Bullosa Patients

Conditions: Epidermolysis Bullosa; Chronic Skin Ulcer
NCT03928093

Recruiting

Pregabalin Treatment for RDEB Pain and Itch

Conditions: Pain, Neuropathic; Itch; Epidermolysis Bullosa
NCT03836001

Recruiting

A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa

Conditions: Epidermolysis Bullosa
NCT03786237

Recruiting

Rigosertib for RDEB-SCC

Conditions: Epidermolysis Bullosa Dystrophica; Squamous Cell Carcinoma
NCT03752905

Active, not recruiting

A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Conditions: Recessive Dystrophic Epidermolysis Bullosa
NCT03730584

Active, not recruiting

Evaluation of the Efficacy of ROPIVACAINE in Children and Young Adults With Hereditary Epidermolysis Bullosa

Conditions: Epidermolysis Bullosa
NCT03640871

Unknown status

HEAL Study: Healing Results, Efficacy and Acceptability of a New Contact Layer

Conditions: Wound
NCT03605069

Recruiting

Topical QR-313 in Dominant Dystrophic Epidermolysis Bullosa (DDEB) or Recessive Dystrophic Epidermolysis Bullosa (RDEB) Due to Mutation(s) in Exon 73 of the COL7A1gene

Conditions: Epidermolysis Bullosa Dystrophica, Recessive; Epidermolysis Bullosa Dystrophica, Dominant
NCT03578029

Recruiting

Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa

Conditions: Junctional Epidermolysis Bullosa; Dystrophic Epidermolysis Bullosa
NCT03536143

Active, not recruiting

Topical Beremagene Geperpavec (KB103) Gene Therapy to Restore Functional Collagen VII for the Treatment of Dystrophic Epidermolysis Bullosa

Conditions: Dystrophic Epidermolysis Bullosa
NCT03529877

Recruiting

Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa

Conditions: Recessive Dystrophic Epidermolysis Bullosa
NCT03526159

Recruiting

Gentamicin for Junctional Epidermolysis Bullosa

Conditions: Junctional Epidermolysis Bullosa
NCT03490331

Active, not recruiting

Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With JEB (HOLOGENE17)

Conditions: Junctional Epidermolysis Bullosa
NCT03472287

Completed

To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)

Conditions: Epidermolysis Bullosa (EB); Epidermolysis Bullosa Simplex; Dystrophic Epidermolysis Bullosa; Junctional Epidermolysis Bullosa
NCT03468322

Completed

A Double-blind, Intra-individual Comparison, POC Trial of AC-203 in EB Patients

Conditions: Inherited Epidermolysis Bullosa
NCT03453632

Recruiting

Injections of Botulinic Toxin in Plantar Lesions of Localized Epidermolysis Bullosa Simplex

Conditions: Epidermolysis Bullosa Simplex
NCT03392909

Recruiting

Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Conditions: Recessive Dystrophic Epidermolysis Bullosa
NCT03389308

Completed

Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex

Conditions: Epidermolysis Bullosa; Epidermolysis Bullosa Simplex
NCT03269474

Active, not recruiting

Computational Drug Repurposing for EBS

Conditions: Epidermolysis Bullosa Simplex; Healthy; Genetic Skin Disease
NCT03241628

Completed

Proof of Concept Study for a Dressing Glove

Conditions: Epidermolysis Bullosa Dystrophica
NCT03183934

Unknown status

A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical Trial

Conditions: Dystrophic Epidermolysis Bullosa
NCT03158662

Completed

Survey to Identify Burdens and Unmet Needs of Patients With Epidermolysis Bullosa

Conditions: Epidermolysis Bullosa
NCT03154333

Terminated

Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)

Conditions: Epidermolysis Bullosa Simplex
NCT03068780

Active, not recruiting

Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa

Conditions: Epidermolysis Bullosa
NCT03016715

Unknown status

Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study

Conditions: Epidermolysis Bullosa Simplex; Epidermolysis Bullosa Simplex Kobner; Weber-Cockayne Syndrome
NCT03012191

Completed

Gentamicin for RDEB

Conditions: Recessive Dystrophic Epidermolysis Bullosa
NCT02984085

Active, not recruiting

Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With RDEB.

Conditions: Recessive Dystrophic Epidermolysis Bullosa
NCT02960997

Active, not recruiting

Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study

Conditions: Epidermolysis Bullosa Simplex; Epidermolysis Bullosa Simplex Kobner; Weber-Cockayne Syndrome
NCT02810951

Active, not recruiting

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Conditions: Epidermolysis Bullosa Dystrophica, Recessive
NCT02793960

Completed

Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa

Conditions: Epidermolysis Bullosa
NCT02698735

Completed

Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation Patients

Conditions: Recessive Dystrophic Epidermolysis Bullosa
NCT02670837

Recruiting

Study of Cellutome System for Treatment of Individual Lesions in EB Pts

Conditions: Epidermolysis Bullosa
NCT02670330

Terminated

Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa

Conditions: Epidermolysis Bullosa
NCT02654483

Completed

Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients

Conditions: Epidermolysis Bullosa; Pruritus
NCT02592954

Completed

Effect of Broccoli Sprout Extract on Keratinocyte Differentiation in Normal Skin

Conditions: Epidermolysis Bullosa Simplex; Pachyonychia Congenita
NCT02582775

Recruiting

MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs

Conditions: Epidermolysis Bullosa
NCT02579369

Unknown status

Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa

Conditions: Dystrophic Epidermolysis Bullosa

Clinical Trials on Epidermolysis Bullosa

Recent CRA jobs

Strategic Solutions Lead - Remote Based

Associate Director, Study Start Up - France

Country Approval Specialist - Beijing, Shanghai, Homebased

Associate Director, SSU Project Mgmt (Line Management)

Housekeeper - Per Diem

Associate Research Scientist - R&D, LC/MS

Clinical Data Associate - Functional Service Partnership - Contract Opportunity

Associate Metrologist - Analytical Instrument Specialist

Clinical Data Associate - Functional Service Partnership - Temporary Opportunity

Senior iCRA